Why Is SUPERNUS PHARMACEUTI (SUPN) Stock Moving Today?

Why SUPN stock is up today

Supernus Pharmaceuticals shares surged 9.15% to $47.20 on Monday, driven by a combination of a revenue beat, a raised 2026 guidance, and the announcement of a merger with Indivior. The stock opened with a slight gap down but quickly reversed course, reaching a session high of $47.39 before settling near that level. The merger with Indivior, a proposed all-stock, tax-free transaction, is expected to create a combined CNS-focused biopharmaceutical company.

What Happened

The 8-K filing from Supernus on August 3 confirmed the merger with Indivior, which will combine their commercial portfolios targeting CNS and opioid use disorders. The companies are marketing nearly a dozen neurological drugs, and the merger is expected to create a stronger entity with potential annual revenue of $2 billion. Supernus also reported second-quarter revenue of $219.058 million, which beat estimates of $204.962 million. However, the company’s adjusted EPS of $0.53 was offset by a non-cash impairment charge that led to a reported EPS of $(1.01), missing the $0.07 estimate.

Retail traders on social platforms are discussing the stock as potentially oversold, and recent coverage from Yahoo Finance and Benzinga has highlighted the strategic and financial implications of the merger. The stock’s sharp intraday move reflects optimism about the combined entity’s potential and Supernus’ recent earnings performance.

What The Data Shows

The stock opened at $42.97, below the previous close of $43.25, but quickly reversed to a high of $47.39. Volume was 0.1 million shares, or 0.2 times the 3-month average. The stock has traded within a 52-week range of $35.51 to $59.68, and over the last 8 sessions, it declined 4.4% from $46.20 to $44.17. Supernus has a market cap of $2.7 billion, unprofitable with a TTM EPS of -1.91, and a revenue growth of 24.9% TTM. The stock has a beta of 0.56, indicating lower volatility than the market.

What To Watch

The next key event for Supernus will be the progression of the merger with Indivior. Investors should monitor the regulatory approval process and the integration of the two companies' portfolios. Coverage breadth is also a factor to watch, as the 6 stories from 4 sources in the last 36 hours suggest growing interest in the stock.